Skip to main content

Start ENTRESTO® with confidence

ENTRESTO is available in 3 dosage strengths1
dosing_desktop.png

Pills shown not actual size.

How to prescribe ENTRESTO to your adult patients

Choose initial dose of ENTRESTO based on current treatment and titrate to the target dose1

  • ENTRESTO is contraindicated with concomitant use of an ACEi and in patients with a history of angioedema related to previous ACEi or ARB therapy1

  • Avoid use of ENTRESTO with an ARB, because ENTRESTO contains the angiotensin II receptor blocker valsartan1

Unless your patient is on a high ACEi/ARB dose, start ENTRESTO at 24/26 mg twice daily and double the dose every 2 to 4 weeks, as tolerated by the patient. When switching from an ACEi, be sure to allow for a 36-hour washout period prior to initiating ENTRESTO.1

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1

Important Safety Information

BOXED WARNING: FETAL TOXICITY

  • When pregnancy is detected, discontinue ENTRESTO as soon as possible
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus

ENTRESTO is contraindicated in patients with hypersensitivity to any component...

Indication

ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.

LVEF is a variable measure, so use clinical judgment in deciding whom to treat.

Click or scroll to see IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING AND INDICATION

Definitions
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin ‖ receptor blocker; LAE, left atrial enlargement; LVH, left ventricular hypertrophy.

References
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
2. Senni M, McMurray JJV, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18(9):1193-1202. doi:10.1002/ejhf.548